Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma

Digestive Diseases and Sciences

Volumn 60, Issue 10, 2015, Pages 3011-3018

  Wang, Xin ^a   Han, Longzhi ^a   Zhang, Jianjun ^a   Xia, Qiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Cell proliferation; Cell senescence; Hepatocellular carcinoma; Neurensin 2; Patient prognosis

Indexed keywords

CELL MEMBRANE PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NEURENSIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; MTOR PROTEIN, HUMAN; NRSN2 PROTEIN, HUMAN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE;

ADOLESCENT; ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL FUNCTIONS; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL AGING; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; CHI SQUARE DISTRIBUTION; EPIDEMIOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOPSY, NEEDLE; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL AGING; CELL PROLIFERATION; CELL SURVIVAL; CHI-SQUARE DISTRIBUTION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MEMBRANE PROTEINS; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84942200197     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3736-3     Document Type: Article

References (23)

1. Parkin DM. Global cancer statistics in the year 2000.
2. Poon RT-P, Fan S-T, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10–24.
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment nature reviews. Cancer. 2006;6:674–687.
4. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2011;21:35–43.
5. Zender L, Xue W, Zuber J, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell. 2008;135:852–864.
6. Nakanishi K, Ida M, Suzuki H, et al. Molecular characterization of a transport vesicle protein Neurensin-2, a homologue of Neurensin-1, expressed in neural cells. Brain Res. 2006;1081:1–8.
7. An Y, Amr SS, Torres A, et al. SOX12 and NRSN2 are candidate genes for 20p13 subtelomeric deletions associated with developmental delay. Am J Med Genet Part B Neuropsychiatr Genet. 2013;162b:832–840.
8. Ma HQ, Liang XT, Zhao JJ, et al. Decreased expression of Neurensin-2 correlates with poor prognosis in hepatocellular carcinoma. World J Gastroenterol. 2009;15:4844–4848.
9. Feng MX, Ma MZ, Fu Y, et al. Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation. Mol Cancer. 2014;13:226.
10. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–1326.
11. Dent P. Crosstalk between ERK, AKT, and cell survival. Cancer Biol Ther. 2014;15:245–246.
12. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005;120:513–522.
13. Pelicci PG. Do tumor-suppressive mechanisms contribute to organism aging by inducing stem cell senescence? J Clin Investig. 2004;113:4–7.
14. Jackson JG, Pereira-Smith OM. p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts. Cancer Res. 2006;66:8356–8360.
15. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797–803.
16. Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol. 2011;7:1149–1167.
17. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol. 2010;27:255–261.
18. Reed JC. Bcl-2 family proteins. Oncogene. 1998;17:3225–3236.
19. Coultas L, Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol. 2003;13:115–123.
20. Wang J-M, Chao J-R, Chen W, Kuo M-L, Yen JJ-Y, Yang-Yen H-F. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol. 1999;19:6195–6206.
21. Mooi WJ, Peeper DS. Oncogene-induced cell senescence—halting on the road to cancer. N Engl J Med. 2006;355:1037–1046.
22. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res. 2003;63:2705–2715.
23. Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene. 2002;21:1299–1303.